Decipher- Genomic Test especially for patients after Radical Prostatecomy

Decipher Prostate Cancer Classifier is validated specifically for men faced with treatment decisions after radical prostatectomy. It classifies the patient’s tumor independently of PSA rise and other adverse features. Decipher measures and analyzes the activity of 22 genetic markers expressed in the prostate cancer tumor to measure the tumor’s biological potential for metastasis after surgery. These 22 markers associated with aggressive disease were discovered from genome-wide search algorithms of more than a million markers and have been extensively validated in collaboration with leading academic medical institutions. The Decipher test provides physicians with additional information and helps them and their patients make timely and confident decisions for optimal treatment and management of prostate cancer.
Decipher is currently available to select physicians and their patients as a part of ongoing clinical studies. If you are a physician interested in participating in these studies, please contact us at decipher@genomedx.com

This entry was posted in Biomarker, Treatments for Prostate Cancer and tagged , . Bookmark the permalink.